Leaving no-one behind: A set of policy principles to meet the global challenge of Rare Diseases
Rare diseases pose unique challenges to patients, their families, society, healthcare professionals and healthcare systems.
Read more
Rare diseases pose unique challenges to patients, their families, society, healthcare professionals and healthcare systems.
Read more
Rare diseases are a group of conditions which affect very small numbers of people. Definitions vary, although generally a disease is considered rare if it affects fewer than 1-5 individuals per 10,000 in the general population.
Read more
We need an informed societal debate on how much prolonging life should be allowed to cost (Note to our readers: This is a re-posting that was first published on Monday 27 February in the Basler Zeitung) Recently, the Secretary of Health for the Swiss canton of Zurich, Thomas Heiniger, called for a “fact-based societal debate” on...
Read moreIFPMA, the international association representing the innovative biopharmaceutical industry, welcomes the G-FINDER 2016[1] results, which shows that industry consolidated its status as a main funder of neglected disease R&D in 2015. These R&D efforts are a critical area where the research-based biopharmaceutical industry supports the global health community in putting an end to some of...
Read moreGeneva, 10 February 2017 – IFPMA has just published its 2017 facts & figures report containing a wealth of data and trends on biopharmaceutical innovation, global health, and the economic footprint of the industry. The Report provides an overview of our R&D pipeline, with 56 new medicinal products launched in 2015, more than 7,000 compounds...
Read moreToday the International Federation of Pharmaceutical Wholesalers (IFPW) begins its role as secretariat of Fight the Fakes, the global campaign to raise awareness of the threat fake medicines pose to people and public health. Launched in November 2013, Fight the Fakes has grown into a coalition of over 30 organizations, including healthcare professionals, academia, NGOs,...
Read moreThomas B. Cueni has taken up office as Director General of IFPMA on February 1, representing the interests of the research-based biopharmaceutical industry at a global level. Thomas Cueni is highly respected across the biopharmaceutical sector, having served for many years as Secretary General of Interpharma, the association of pharmaceutical research companies in Switzerland. He...
Read moreIn the wake of WEF Davos, there is consensus more than ever that the private sector has a role to play in achieving the 2030 Sustainable Development Goals. From investment opportunities to research capabilities, collective ambitions to sharing information, many sectors see the value of coalitions and opportunities for the private sector to plug the...
Read moreThe International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and its members, with an additional contribution from Bristol-Myers Squibb, will support the IAEA’s Programme of Action for Cancer Therapy (PACT) and will focus on critical areas such as awareness raising, resource mobilization, and capacity building. First collaboration of its kind will open new avenues for...
Read more